Skip to main content

NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 European Hematology Association Annual Meeting


GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-002 will be presented in a poster session at the European Hematology Association (EHA) 2021 Annual Meeting being held virtually from June 11 – June 17, 2021.

Poster Presentation:

Title: Preliminary Analysis of a Phase 1 Study of NEXI-002 Autologous Multi-Agent-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)

Abstract #: EP740

Session Title: Poster Session: Gene therapy, cellular immunotherapy and vaccination - Clinical

Press Release